Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Clinical Care/Education/Nutrition

Effects of Isoflavone Dietary Supplementation on Cardiovascular Risk Factors in Type 2 Diabetes

  1. Susana González, MRCP1,
  2. Vijay Jayagopal, MD2,
  3. Eric S. Kilpatrick, MD3,
  4. Tom Chapman, FR PHARM S4 and
  5. Stephen L. Atkin, PHD1
  1. 1Department of Medicine, University of Hull, Hull, U.K.
  2. 2Department of Medicine, York General Hospital, York, U.K.
  3. 3Department of Biochemistry, Hull Royal Infirmary, Hull, U.K.
  4. 4Essential Nutrition, Brough, U.K.
  1. Address correspondence and reprint requests to Dr. Susana González, Huddersfield NHS Trust, Acre Street, Huddersfield, HD3 3EA, U.K. Email: ucm_sg{at}hotmail.com
Diabetes Care 2007 Jul; 30(7): 1871-1873. https://doi.org/10.2337/dc06-1814
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading
  • CVD, cardiovascular disease
  • HOMA-IR, homeostasis model assessment of insulin resistance

A diet supplemented with soy protein and isoflavones has been shown to reduce cardiovascular risk factors in postmenopausal women with type 2 diabetes. However, it remains unclear which component is responsible for these effects. Our aim was to determine whether the addition of isoflavones alone modifies cardiovascular disease risk markers in this group of patients. Cardiovascular disease (CVD) is the leading cause of mortality in women in developed countries (1), and women with diabetes are four times more likely to die from CVD than men (2). Among other factors, postmenopausal estrogen depletion, greater insulin resistance, and dyslipidemia (3,4) may contribute to high risk of accelerated CVD.

Modification of lifestyle is important to reduce CVD risk factors and delay progression of type 2 diabetes–associated complications. In particular, the addition of oral supplements, such as soy products, as part of a healthy diet has attracted recent interest because of their beneficial effects on lipid profiles (5–10). However, scant information is available on the effects of soy in individuals with type 2 diabetes (11–13), who are at higher risk due to hyperlipidemia, lower HDL levels, and abnormalities in LDL/lipoprotein composition (14). It also remains unclear whether a beneficial effect can be attributed to the soy protein or isoflavones.

We have shown that soy protein combined with isoflavones can improve glycemic control, insulin resistance, and lipids in patients with type 2 diabetes (11). Therefore, our aim was to determine if this effect was due to the isoflavone component alone.

RESEARCH DESIGN AND METHODS—

This was a randomized, double-blind, placebo-controlled, crossover study with a 4-week washout period separating the placebo and active phases (12 weeks each). Subjects provided informed consent. Randomization was performed using a random number generator.

Thirty-two Caucasian, postmenopausal women with diet-controlled type 2 diabetes (according to World Health Organization criteria) (15) and amenorrhoa (for >1 year) were recruited. Exclusion criteria were breast/uterine cancer; uncontrolled hypothyroidism; and treatment with oral hypoglycemic agents, insulin, estrogens, or statins initiated <4 months before the trial.

Baseline characteristics are included in Table 1. Six subjects withdrew from the study: one required a cholecystectomy and one a coronary angioplasty, one had an acute attack of polymyalgia rheumatica requiring steroids, and three were unable to comply with study requirements.

Intervention

The soy preparation (Essential Nutrition) contained 132 mg isoflavones (53% genistein, 37% daidzein, and 10% glycitein). It was devoid of soluble fiber. The placebo was an identical tablet of microcrystalline cellulose. Compliance was monitored by counting returned medication.

Study measurements

Venous blood samples were collected at each visit after a 12-h overnight fast. A1C, glucose, and lipid levels were measured using standard methods. LDL cholesterol was calculated using the Friedewald equation and insulin resistance using the homeostasis model assessment of insulin resistance (HOMA-IR) method (16).

Statistical analysis

Mean percentage changes obtained at the end of isoflavone treatment were compared with those at the end of the placebo phase, using the paired Student's t test if they followed a Gaussian distribution or the Wilcoxon's signed-rank test if those changes violated the assumption of normality when tested using the Kolmogorov-Smirnov test (C-reactive protein and HOMA-IR data). The period effect (calculated by comparing the mean difference between placebo and isoflavone treatment in the group starting on placebo with that in the group starting on isoflavones) and the carryover effect (comparing baseline values for each treatment group) were tested using Student's t test. The results were considered statistically significant if the two-tailed P value was <0.05. Statistical analysis was performed using SPSS (version 15). P values are included in Table 1.

RESULTS—

A total of 26 patients completed the study. No period or carryover effects were detected. Both study preparations were well tolerated, with >90% compliance.

Effects on glycemic control and other effects

There were no significant differences detected in glucose, A1C, HOMA-IR, total cholesterol, triglycerides, or HDL and LDL cholesterol levels between isoflavone and placebo phases. Likewise, no significant differences were seen in BMI, blood pressure, or C-reactive protein between treatment and placebo phases.

CONCLUSIONS—

This study showed that soy isoflavones alone do not confer significant cardiovascular protection or positive effects on glycemic control in this group of patients. This is in accord with studies with red clover isoflavones in diabetes that observed no change of plasma lipoproteins or glycated hemoglobin, although basal endothelial function (17) and arterial compliance (18) did alter. However, it is possible that effects mediated by the isoflavones are too modest to be detected over the 3-month study period.

Epidemiological studies (19,20) have indicated that there is no significant association between the standard western dietary intake of isoflavones (0.369 –0.770 mg/day) and the reduction of cardiovascular events or lipid levels in different cohorts of postmenopausal women over prolonged periods of time (4–6 years). Our subjects received >150 times this amount, yet no significant changes were observed over a 3-month period. The dose of isoflavones given was the same we used with 30 g soy protein, which reduced these cardiovascular and glycemic parameters within the same time frame (11). In addition, supplementation with isoflavones alone (40–150 mg/day) in subjects without diabetes showed that there was no change in lipid profile in peri/postmenopausal women, both healthy and mildly hypercholesterolemic (18,21,22).

Conversely, isolated soy protein has been shown to reduce total cholesterol (9.3%), LDL cholesterol (12.9%), and triglycerides (10.5%) (23). The FDA recommends that 25 g soy protein/day may reduce CVD (24), since beneficial effects have also been observed with different combinations of soy protein and isoflavones in healthy or mildly hypercholesterolemic postmenopausal/perimenopausal women (9,10,25) and in men/postmenopausal women with type 2 diabetes (11,12).

In conclusion, isoflavones alone did not alter CVD markers over a 3-month period. This suggests that either the soy protein component alone or a synergistic effect between the protein with the isoflavones may be responsible for any CVD changes.

View this table:
  • View inline
  • View popup
Table 1—

Subject characteristics and effects on CVD risk at the start of the trial and after 3 months of treatment

Footnotes

  • Published ahead of print at http://care.diabetesjournals.org on 27 April 2007. DOI: 10.2337/dc06-1814.

    A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

    The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C Section 1734 solely to indicate this fact.

    • Accepted April 18, 2007.
    • Received December 15, 2006.
  • DIABETES CARE

References

  1. ↵
    World Health Organization: The World Health Report 2003: Shaping the Future. Geneva, World Health Org., 2003, p. 1–5
  2. ↵
    Greenland P, Reicher-Reiss H, Goldbourt U, Behar S: In-hospital and 1-year mortality in 1,524 women after myocardial infarction: comparison with 4,315 men. Circulation 83:484–491, 1991
    OpenUrlAbstract/FREE Full Text
  3. ↵
    Mercuro G, Zoncu S, Dragoni F: Gender differences in cardiovascular risk factors. Ital Heart J 4:363–366, 2003
    OpenUrlPubMed
  4. ↵
    Crespo CJ, Smit E, Snelling A, Sempos CT, Andersen RE: Hormone replacement therapy and its relationship to lipid and glucose metabolism in diabetic and nondiabetic postmenopausal women: results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care 25:1675–1680, 2002
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Ridges L, Sunderland R, Moerman K, Meyer B, Astheimer L, Howe P: Cholesterol lowering benefits of soy and linseed enriched foods. Asia Pac J Clin Nutr 10:204–211, 2001
    OpenUrlCrossRefPubMedWeb of Science
  6. Vigna GB, Pansini F, Bonaccorsi G, Albertazzi P, Donega P, Zanotti L, De Aloysio D, Mollica G, Fellin R: Plasma lipoproteins in soy-treated postmenopausal women: a double-blind, placebo-controlled trial. Nutr Metab Cardiovasc Dis 10:315–322, 2000
    OpenUrlPubMedWeb of Science
  7. Scheiber MD, Liu JH, Subbiah MT, Rebar RW, Setchell KD: Dietary inclusion of whole soy foods results in significant reductions in clinical risk factors for osteoporosis and cardiovascular disease in normal postmenopausal women. Menopause 8:384–392, 2001
    OpenUrlCrossRefPubMedWeb of Science
  8. Puska P, Korpelainen V, Hoie LH, Skovlund E, Lahti T, Smerud KT: Soy in hypercholesterolaemia: a double-blind, placebo-controlled trial. Eur J Clin Nutr 56:352–357, 2002
    OpenUrlCrossRefPubMed
  9. ↵
    Teede HJ, Dalais FS, Kotsopoulos D, Liang YL, Davis S, McGrath BP: Dietary soy has both beneficial and potentially adverse cardiovascular effects: a placebo-controlled study in men and postmenopausal women. J Clin Endocrinol Metab 86:3053–3060, 2001
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    Wangen KE, Duncan AM, Xu X, Kurzer MS: Soy isoflavones improve plasma lipids in normocholesterolemic and mildly hypercholesterolemic postmenopausal women. Am J Clin Nutr 73:225–231, 2001
    OpenUrlAbstract/FREE Full Text
  11. ↵
    Jayagopal V, Albertazzi P, Kilpatrick ES, Howarth EM, Jennings PE, Hepburn DA, Atkin SL: Beneficial effects of soy phytoestrogen intake in postmenopausal women with type 2 diabetes. Diabetes Care 25:1709–1714, 2002
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Hermansen K, Sondergaard M, Hoie L, Carstensen M, Brock B: Beneficial effects of a soy-based dietary supplement on lipid levels and cardiovascular risk markers in type 2 diabetic subjects. Diabetes Care 24:228–233, 2001
    OpenUrlAbstract/FREE Full Text
  13. ↵
    Anderson JW, Blake JE, Turner J, Smith BM: Effects of soy protein on renal function and proteinuria in patients with type 2 diabetes. Am J Clin Nutr 68:1347S–1353S, 1998
    OpenUrlAbstract
  14. ↵
    Laakso M: Dyslipidemia, morbidity, and mortality in non-insulin-dependent diabetes mellitus: lipoproteins and coronary heart disease in non-insulin-dependent diabetes mellitus. J Diabetes Complications 11:137–141, 1997
    OpenUrlPubMed
  15. ↵
    World Health Organization, Department of Non-Communicable Disease Surveillance: Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Geneva, World Health Org., 1999, p. 1–59
  16. ↵
    Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419, 1985
    OpenUrlCrossRefPubMedWeb of Science
  17. ↵
    Howes JB, Tran D, Brillante D, Howes LG: Effects of dietary supplementation with isoflavones from red clover on ambulatory blood pressure and endothelial function in postmenopausal type 2 diabetes. Diabetes Obes Metab 5:325–332, 2003
    OpenUrlCrossRefPubMedWeb of Science
  18. ↵
    Nestel PJ, Pomeroy S, Kay S, Komesaroff P, Behrsing J, Cameron JD, West L: Isoflavones from red clover improve systemic arterial compliance but not plasma lipids in menopausal women. J Clin Endocrinol Metab 84:895–898, 1999
    OpenUrlCrossRefPubMedWeb of Science
  19. ↵
    van der Schouw YT, Kreijkamp-Kaspers S, Peeters PH, Keinan-Boker L, Rimm EB, Grobbee DE: Prospective study on usual dietary phytoestrogen intake and cardiovascular disease risk in Western women. Circulation 111:465–471, 2005
    OpenUrlAbstract/FREE Full Text
  20. ↵
    De Kleijn MJJ, Van der Schonw YT, Wilson PWF, Grobbee DE, Jacques PF: Dietary intake of phytoestrogens is associated with a favorable metabolic cardiovascular risk profile in postmenopausal U.S. women: the Framingham Study. J Nutr 132:276–282, 2002
    OpenUrlAbstract/FREE Full Text
  21. ↵
    Simons LA, von Konigsmark M, Simons J, Celermajer DS: Phytoestrogens do not influence lipoprotein levels or endothelial function in healthy, postmenopausal women. Am J Cardiol 85:1297–1301, 2000
    OpenUrlCrossRefPubMedWeb of Science
  22. ↵
    Dewell A, Hollenbeck CB, Bruce B: The effects of soy-derived phytoestrogens on serum lipids and lipoproteins in moderately hypercholesterolemic postmenopausal women. J Clin Endocrinol Metab 87:118–121, 2002
    OpenUrlCrossRefPubMedWeb of Science
  23. ↵
    Anderson JW, Johnstone BM, Cook-Newell ME: Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med 333:276–282, 1995
    OpenUrlCrossRefPubMedWeb of Science
  24. ↵
    Health Claims: Soy Protein and Risk of Coronary Heart Disease. Code of Federal Regulations Title 21, Pt. 101.82, 2002 ed.
  25. ↵
    Washburn S, Burke GL, Morgan T, Anthony M: Effect of soy protein supplementation on serum lipoproteins, blood pressure, and menopausal symptoms in perimenopausal women. Menopause 6:7–13, 1999
    OpenUrlPubMed
PreviousNext
Back to top
Diabetes Care: 30 (7)

In this Issue

July 2007, 30(7)
  • Table of Contents
  • About the Cover
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Effects of Isoflavone Dietary Supplementation on Cardiovascular Risk Factors in Type 2 Diabetes
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Effects of Isoflavone Dietary Supplementation on Cardiovascular Risk Factors in Type 2 Diabetes
Susana González, Vijay Jayagopal, Eric S. Kilpatrick, Tom Chapman, Stephen L. Atkin
Diabetes Care Jul 2007, 30 (7) 1871-1873; DOI: 10.2337/dc06-1814

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Effects of Isoflavone Dietary Supplementation on Cardiovascular Risk Factors in Type 2 Diabetes
Susana González, Vijay Jayagopal, Eric S. Kilpatrick, Tom Chapman, Stephen L. Atkin
Diabetes Care Jul 2007, 30 (7) 1871-1873; DOI: 10.2337/dc06-1814
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • RESEARCH DESIGN AND METHODS—
    • RESULTS—
    • CONCLUSIONS—
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Increased Second Trimester Maternal Glucose Levels Are Related to Extremely Large-for-Gestational-Age Infants in Women With Type 1 Diabetes
  • The Effects of Hypogonadism on Body Composition and Bone Mineral Density in Type 2 Diabetic Patients
  • Effect of Renal Insufficiency on the Pharmacokinetics of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor
Show more Clinical Care/Education/Nutrition

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.